Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Clin Lung Cancer. 2012 Sep;13(5):334-9. doi: 10.1016/j.cllc.2012.01.004. Epub 2012 Mar 14.
In light of recent advances in individualized therapy for non-small-cell lung cancer (NSCLC), molecular and histologic profiling is essential for guiding therapeutic decisions. Results of these analyses may have implications for both response (eg, molecular testing for EGFR [epidermal growth factor receptor] mutations) and safety (eg, contraindications for squamous histology) in NSCLC. Most patients with NSCLC present with unresectable advanced disease; therefore, greater emphasis is being placed on minimally invasive tissue acquisition techniques, such as small biopsy and cytology specimens. Due to the need for increasing histologic and molecular information and increasingly smaller tissue sample sizes, efforts must be focused on optimizing tissue acquisition and the development of more sensitive molecular assays. Recent advances in tissue acquisition techniques and specimen preservation may help to address this challenge and lead to enhanced personalized treatment in NSCLC.
鉴于非小细胞肺癌 (NSCLC) 个体化治疗的最新进展，分子和组织学分析对于指导治疗决策至关重要。这些分析结果可能对 NSCLC 的反应（例如，表皮生长因子受体 [EGFR] 突变的分子检测）和安全性（例如，鳞状组织学的禁忌症）都有影响。大多数 NSCLC 患者表现为不可切除的晚期疾病；因此，越来越重视微创组织获取技术，如小活检和细胞学标本。由于需要更多的组织学和分子信息以及越来越小的组织样本量，必须集中精力优化组织获取和开发更敏感的分子检测方法。组织获取技术和标本保存的最新进展可能有助于解决这一挑战，并为 NSCLC 提供更好的个性化治疗。
